Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
 editing efficiency can be significantly increased to 65–100% if the gRNAs are fused to a mobile RNA sequence, such as truncated FLOWERING LOCUS T (FT) [10]. This suggests that a mobile RNA sequence allows gRNAs to move between cells, thus enabling targeting of genomic sequences in meristem and germline cells. It may therefore be possible to fuse the Cas9/gRNA system with a mobile RNA sequence, and then use the corresponding engineered SYNV virus to infect plants, thus achieving genome editing completely independently of tissue culture (Figure 1). With these improvements, one can envisage editing a trait of choice in virtually any plant, be it in the field or elsewhere, to obtain transgene-free genome editing for biotechnological improvement of crops.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (17172403) and the International Cooperation and Exchanges Project of Shaanxi Province (2019KW-047) to H.L. This work is also partially supported by NSF (#1658707) and the Cotton International Cooperation and Exchanges Project of Shaanxi Science Foundation of China (31772403) and the International Science and Technology Cooperation Program of Shaanxi Province (2019SF-654).

References
1. Adli, M. (2018) The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1111
2. Baik, R.O. et al. (2018) Gene editing on center stage. Trends Genet. 34, 600–611
3. Mu, X. et al. (2020) Highly efficient DNA-free plant genome editing using virally delivered CRISPR-Cas9. Nat. Plants 6, 773–779
4. Yip, B.H. (2020) Recent advances in CRISPR/Cas9 delivery strategies. Biomolecules 10, 839
5. Cody, W.B. and Scholthof, H.B. (2019) Plant virus vectors: a new tool for functional genomics. Annu. Rev. Phytopathol. 57, 211–230
6. Wang, Q. et al. (2015) Rescue of a plant negative-strand RNA virus from cloned cDNA: insights into enveloped plant virus movement and morphogenesis. PLoS Pathog. 11, e1005223
7. German, T.L. et al. (2020) New technologies for studying negative-strand RNA viruses in plants and arthropod hosts. Mol. Plant-Microbe Interact. 33, 382–390
8. Hu, J. et al. (2019) A barley stripe mosaic virus-based guide RNA delivery system for targeted mutagenesis in wheat and maize. Mol. Plant Pathol. 20, 1463–1474
9. Al, Z. et al. (2015) Efficient virus-mediated genome editing in plants using the CRISPR/Cas9 system. Mol. Plant 8, 1286–1291
10. Ellison, E.E. et al. (2020) Multiplexed heritable gene editing using RNA viruses and mobile single guide RNAs. Nat. Plants 6, 620–624

Glossary
Expression quantitative trait locus (eQTL): a genomic locus that explains the variation in gene expression of nearby genes.

Minor allele frequency (MAF): frequency at which the second most common allele occurs in a given population.

Forum
Host Polymorphisms May Impact SARS-CoV-2 Infectivity
Patrick Brest,1 Sadal Refae,2,3,5 Baharia Mograbi,1 Paul Hofman,1,4 and Gerard Milano2,*

Based on a broad public database compilation, we support the hypothesis that germlinal polymorphisms may regulate the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular target itself and proteases controlling the process of its shedding or, conversely, its internalization. Consequently, a genetic influence on individual susceptibility to coronavirus disease 2019 (COVID-19) infection is strongly suspected.

General Background
In addition to the need for virus detection, evaluation of individual serological response [1], and biological analytical tools to manage COVID-19 on a population level, there is an urgent need to obtain objective information to identify at-risk individuals and to understand the marked variability in the severity of the disease in general, as well as in given populations. A current hypothesis is that SARS-CoV-2 clinical manifestations are governed by human genetics [2]. Thus, in this context, here we develop two complementary themes: (i) a more thorough examination of the membrane shedding of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 cellular target, and its potential repercussion on virus propagation; and (ii) a description of the interindividual variability of the genes (SNPs) involved in ACE2 processing and their potential impact on the risk of contracting COVID-19.

ACE2 Expression and COVID-19
Chen et al. recently examined a large Genotype–Tissue Expression (GTEx) database and investigated the expression of ACE2 in different human tissues [3]. The authors stressed that, counterintuitively, expression of the SARS-CoV-2 target was inversely related to certain risk factors, showing higher levels in Asian females compared with Asian males and a significant decrease in patients with type 2 diabetes mellitus. Globally, at a population level, there was a negative correlation between ACE2 expression and COVID-19 severity. Recent data provide evidence that ACE2 is effectively shed from membranes, a process that is fine-tuned at different levels [4] involving two cell membrane proteases: disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) and transmembrane protease serine 2 (TMPRSS2) [4]. More precisely, ADAM17 acts directly on ACE2
and leads to ACE2 shedding into the extracellular cellular space, while TMPRSS2 cleaves not only ACE2, but also the S protein of SARS-CoV-2, thus leading to membrane fusion and cellular uptake of the virus. Consequently, while ADAM17 and TMPRSS2 both act on ACE2, they may have opposite effects on net ACE2 shedding (Figure 1). When the respective proteolytic activities of ADAM17 and TMPRSS2 result in more ACE2 shedding than internalization, it follows that this situation may constitute a natural barrier to infection. This could be due to the interaction between soluble ACE2 with the virus at a distance from sensitive tissues. Subsequently, on this basis, one can hypothesize that, when the viral load is high, the shedding barrier effect is overwhelmed, thus facilitating subsequent infection.

**ACE2, TMPRSS2, and ADAM17 Gene Polymorphisms**

Cao et al. [5] compiled a database analysis of all 1700 variants in the region of the ACE2 gene located on the X chromosome. They identified 15 unique expression quantitative trait loci (eQTLs; see Glossary) variants [14 SNPs and 1 insertion/deletion (INDEL)] with higher minor allele frequencies (MAF) in the Asian population than in a European population (MAF of 0.05 versus 0.35–0.48 for the top six most common variants). Interestingly, their data showed that the 11 most common variants (MAF >0.05) were associated with increased expression of ACE2 in tissues, suggesting, according to the authors, a different sensitivity to SARS-CoV-2 infectivity. However, the functional basis of the influence of SNP on ACE2 expression remains to be established.

In this context, we performed a complementary in silico study including SNPs regulating gene expression not only for ACE2, but also for ADAM17 and TMPRSS2 (Table S1 in the supplemental information online). Overall, and based on the ACE2 expression-associated MAF between ethnic populations, it appears that Asians express a higher level of ACE2 than Caucasians, while Africans show an intermediary level of ACE2 expression. This is consistent with the findings previously reported by Cao et al. [5]. It is still debatable whether these differences should be taken into consideration in epidemiological studies on COVID-19 covering ethnic associations with disease occurrence [6]. Importantly, the diseases associated with a high level of SARS-CoV-2 infection (hypertension and diabetes) were found to be related to a lower expression of ACE2, in relation to the respective allelic distribution. This relationship concurs well with the study by Chen et al. pointing towards a negative correlation between ACE2 expression and COVID-19 severity [3].

It has been reported that subjects with rs383510/T and rs2070788/G genotypes of TMPRSS2 located on chromosome 21q22.3 are more prone to develop a severe form of A (H1N1) influenza and acute respiratory distress syndrome [7]. Of note, males have been shown to be more likely to develop a severe form of H1N1 influenza and there is evidence that androgens are positive regulators of TMPRSS2 [8]. Importantly, the alleles at risk (T for rs383510 and G for rs2070788) are linked to increased gene expression (Table S1 in the supplemental information online), logically supporting the hypothesis of a higher level of viral cell entry. It is
tempting to extrapolate this SNP influence to SARS-CoV-2 infectivity.

The ADAM17 locus on chromosome 2p25.1 presents two clusters and three unique SNPs that induce strong differences in terms of allelic profiles between Asian and European populations that are associated with hypertension [9] and/or sepsis [10]. Of note, most of these SNPs are located in the promoter region of ADAM17 and are associated with either positive or negative eQTL, depending on the SNP and the tissue (Table S1 in the supplemental information online). Therefore, there is a strong possibility that genetic polymorphisms influencing ADAM17 expression also contribute to the modulation of ACE2 shedding intensity.

**Practical Consequences**

Taken together, the above-discussed data advocate in favor of a multifactorial genetic impact on the risk of SARS-CoV-2 infectivity and possible disease severity. A relatively simple and easy-to-perform test, such as quantitative PCR [11] or MASSArray[12], would allow large-scale individual SNP profiling for ACE2, ADAM17, and TMPRSS2 to identify possible at-risk populations vulnerable to viral infection. On this basis, a ‘multiSNPs risk score’ could be established that would be applicable to large populations and, thus, it might then be possible to identify subjects carrying a combination of favorable alleles for ACE2, ADAM17, and TMPRSS2 conferring a lesser risk of contracting SARS-CoV-2 infection, and vice versa. Such an analytical strategy was recently developed based on patient genetic characteristics for immunogenetic profiling designed to personalized immunotherapy [12]. A similar supervised genetic approach to COVID-19 risk assessment could complement the current unsupervised GWAS investigations, which require large population studies exploring the whole patient genome for DNA variations in an attempt to explain individual differences in COVID-19 severity (e.g., the Howard Hughes Medical Institute (HHMI) genetic project and the COVID-19 Human Genetic Effort [2]). Ideally, in a final step, a multifactorial predictive index could be established incorporating SNP analysis and other, more established, risk factors.

In summary, until now, genetic influences on COVID-19 interindividual susceptibility have been largely underestimated; thus, we hope that the discussion might fill this gap and will pave the way for confirmatory investigations at experimental and clinical levels.

**Acknowledgments**

The authors would like to thank Jocelyn Gal, Emmanuel Chamorey, George Morgan, and Christiane Brahimi-Horn for helpful comments. Funding is acknowledged from the French Government (Agence Nationale de Recherche, ANR) through the ‘Investments for the Future’ LABEX SIGNALIFE (ANR-11-LABX-0028-01) and (AD-ME project R19162DD); CANC’AIR Genexposomic project, Canceropole PACA; DREAL PACA, ARS PACA, Région Sud, INSERM cancer; INCA Plan Cancer; and Children Medical Safety Research Institute (CMSRI, Vaccinophagy project R17033DJAA).

**Supplemental Information**

Supplemental information associated with this article can be found online https://doi.org/10.1016/j.tig.2020.08.003.

**Resources**

www.hhmi.org/news/patients-with-severe-forms-of-coronavirus-disease-could-offer-clues-to-treatment

1. Université Côte d’Azur, Centre Antiope Lacassagne, CNRS, Inserm, IRCAN, FHU-OncoAge, Nice, F-06189, France
2. Université Côte d’Azur, Centre Antiope Lacassagne, EA7497, Nice, F-06100 France
3. Ministry of National Guard - Health Affairs (NGHA), Al Madinah Kingdom of Saudi Arabia, Riyadh 11426, Saudi Arabia
4. Université Côte d’Azur, CHU-Nice, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Hospital-Integrated Biobank (BB-0033-00025), Nice, F-06001, France
5. *These authors contributed equally.

*Correspondence: gerard.milano@nice.unice.fr (G. Milano).

https://doi.org/10.1016/j.tig.2020.08.003

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**References**

1. Xie, C. et al. (2020) Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int. J. Infect. Dis. 93, 264–267
2. Casanova, J.-L. et al. (2003) A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 181, 1194–1199
3. Chen, J. et al. (2020) Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 19, 202003013014
4. Heurich, A. et al. (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 89, 1203–1207
5. Cao, Y. et al. (2020) Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 4–7
6. Yi, Y. et al. (2020) COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int. J. Biol. Sci. 16, 1753–1766
7. Cheng, Z. et al. (2015) Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A(H1N1) influenza and A(H7N9) influenza. J. Infect. Dis. 212, 1214–1221
8. Lin, B. et al. (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184
9. Li, Y. et al. (2014) Association between ADAM17 promoter polymorphisms and ischemic stroke in a Chinese population. J. Atheroscler. Thromb. 21, 878–893
10. Shao, Y. et al. (2016) Association study between promoter polymorphisms of ADAM17 and progression of sepsis. Cell. Physiol. Biochem. 39, 1247–1261
11. Katsanis, S.H. and Katsanis, N. (2013) Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 14, 415–426
12. Refae, S. et al. (2020) Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest. New Drugs 38, 160–171